Moderna to make mRNA vaccines in Victoria

By Our Reporter
0
601
Photo by Mufid Majnun on Unsplash

Victoria will become the first place in the southern hemisphere to manufacture mRNA vaccines, after the Victorian Government reached an in-principle agreement with the Commonwealth Government and Moderna.

Under the deal—announced by Acting Premier James Merlino and Prime Minister Scott Morrison today—Moderna’s new manufacturing and finishing facilities, and Australian research centre will all be based in Victoria.

The manufacturing facility will be capable of producing up to 25 million vaccine doses per year from 2024, with the capacity to scale up to 100 million doses per year to combat future pandemics, an official press release said.

It is expected to create up to 500 jobs during construction and around 500 ongoing roles—driving the development of a local mRNA ecosystem that does not currently exist in Australia. mRNA has not only created a new frontier for vaccine development but also become a promising new weapon in the fight against a range of diseases.

As well as mRNA COVID vaccines, the new facility will be able to produce other therapeutics which can be used in the treatment of cancer, rare diseases, cellular engineering and protein-replacement therapy.

Most importantly, developing mRNA manufacturing capability in Victoria will provide vaccine security, ensuring manufacturing can be contracted locally to avoid global supply chain issues and creating a more robust defence against future pandemics.

Victoria is already Australia’s leader in pharmaceutical and biological manufacturing, responsible for nearly 60 per cent of Australia’s pharmaceutical exports—making it the state’s highest value advanced manufactured export.

Earlier this year, the Victorian Government announced up to $400 million in funding for a new Australian Institute of Infectious Disease in Victoria to lead the fight against future pandemics.

Victorian scientists and manufacturers recently also created Australia’s first mRNA COVID-19 vaccine candidate—Australia’s first ever mRNA drug product—in just five months, enabling clinical trials to begin in the new year.


Follow The Indian Sun on Twitter | InstagramFacebook

 

Donate To The Indian Sun

Dear Reader,

The Indian Sun is an independent organisation committed to community journalism. We have, through the years, been able to reach a wide audience especially with the growth of social media, where we also have a strong presence. With platforms such as YouTube videos, we have been able to engage in different forms of storytelling. However, the past few years, like many media organisations around the world, it has not been an easy path. We have a greater challenge. We believe community journalism is very important for a multicultural country like Australia. We’re not able to do everything, but we aim for some of the most interesting stories and journalism of quality. We call upon readers like you to support us and make any contribution. Do make a DONATION NOW so we can continue with the volume and quality journalism that we are able to practice.

Thank you for your support.

Best wishes,
Team The Indian Sun

Comments